Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Open accessPublished version of a preprint
The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
Abstract Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest cavity. To expand our understanding of MPM, we conducted a comprehensive integrated genomic study, including the most detailed analysis of BAP1 alterations to date. We identified histology-independent molecular prognostic subsets, and defined a novel genomic subtype with TP53 and SETDB1 mutations and extensive loss of heterozygosity. We also report strong expression of the immune-checkpoint gene VISTA in epithelioid MPM, strikingly higher than in other solid cancers, with implications for the immune response to MPM and for its immunotherapy. Our findings highlight new avenues for further investigation of MPM biology and novel therapeutic options. Significance: Through a comprehensive integrated genomic study of 74 MPMs, we provide a deeper understanding of histology-independent determinants of aggressive behavior, define a novel genomic subtype with TP53 and SETDB1 mutations and extensive loss of heterozygosity, and discovered strong expression of the immune-checkpoint gene VISTA in epithelioid MPM. See related commentary by Aggarwal and Albelda, p. 1508. This article is highlighted in the In This Issue feature, p. 1494
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, a study that explored 74 mesothelioma tumors using a genomic analysis identified TGF-β1 mRNA expression as being correlated with the worst patient prognoses [40].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053
Self-citationThe Life History of 21 Breast Cancers
Nik-Zainal, S., Van Loo, P., Wedge, D. C., Alexandrov, L. B., Greenman, C. D., Lau, K. W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.023 · Cited by 1,443 · cited 1×
“Since MPM with evidence of GNH have typically undergone a genome-doubling event, we were able to assess the timing of this relative to point mutations (30,31).”
BackgroundSelf-citationSomatic mutation in cancer and normal cells
Martincorena, I., & Campbell, P. J. (2015) · Science · doi:10.1126/science.aab4082 · Cited by 1,396 · cited 1×
“This places MPM at the low end of somatic mutation burden among cancers (8).”
BackgroundSelf-citationShen, R., & Seshan, V. E. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw520 · Cited by 1,258
Self-citationBroz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Clock-like mutational processes in human somatic cells
Alexandrov, L. B., Jones, P. H., Wedge, D. C., Sale, J. E., Campbell, P. J., Nik-Zainal, S., & Stratton, M. R. (2015) · Nature Genetics · doi:10.1038/ng.3441 · Cited by 1,058
Self-citationBueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., De Rienzo, A., Modrusan, Z., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 919
Self-citationShen, R., Olshen, A. B., & Ladanyi, M. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp543 · Cited by 849 · cited 1×
“To find out whether multi-platform molecular profiling might provide additional resolution to define prognostic subsets of MPM, we performed integrative clustering across multiple assay platforms using two algorithms: iCluster (32) and PARADIGM (33).”
MethodSelf-citationVaske, C. J., Benz, S. C., Sanborn, J. Z., Earl, D., Szeto, C., Zhu, J., Haussler, D., & Stuart, J. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq182 · Cited by 786
Self-citation
Cited by
Items 101–200 of 675
Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future
Reid, G., Johnson, T. G., & van Zandwijk, N. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00105 · Cited by 42
Self-citationAbbott, D. M., Bortolotto, C., Benvenuti, S., Lancia, A., Filippi, A. R., & Stella, G. M. (2020) · Cancers · doi:10.3390/cancers12051186 · Cited by 42
Zauderer, M. G., Martin, A. S., Egger, J. V., Rizvi, H. A., Offin, M. D., Rimner, A., Adusumilli, P. S., Rusch, V. W., Kris, M. G., Sauter, J. L., et al. (2021) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00104-7 · Cited by 42
Self-citationMesothelioma Malignancy and the Microenvironment: Molecular Mechanisms
Cersosimo, F., Barbarino, M., Lonardi, S., Vermi, W., Giordano, A., Bellan, C., & Giurisato, E. (2021) · Cancers · doi:10.3390/cancers13225664 · Cited by 41
Zhang, Y. Z., Brambilla, C., Molyneaux, P. L., Rice, A. J., Robertus, J. L., Jordan, S. J., Lim, E. K. S., Lang-Lazdunski, L., Begum, S., Dusmet, M. E., et al. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001416 · Cited by 41
Barbosa, B. A., van Asten, S. D., Oh, J. W., Sarasqueta, A. F., Verheij, J., Dijk, F., van Laarhoven, H. W. M., Ylstra, B., García-Vallejo, J. J., van de Wiel, M. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26328-2 · Cited by 41
NF2 alteration in mesothelioma
Sekido, Y., & Sato, T. (2023) · Frontiers in Toxicology · doi:10.3389/ftox.2023.1161995 · Cited by 40
Self-citationPreclinical Models of Malignant Mesothelioma
Testa, J. R., & Berns, A. J. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00101 · Cited by 40
HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer
Ren, Y., Cherukuri, Y., Wickland, D. P., Sarangi, V., Tian, S., Carter, J. M., Mansfield, A. S., Block, M. S., Sherman, M. E., Knutson, K. L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1744947 · Cited by 40
Leal, J. L., Peters, G. D., Szaumkessel, M., Leong, T. Y.-M., Asadi, K., Rivalland, G., Do, H., Senko, C., Mitchell, P. L. R., Quing, C. Z., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.05.019 · Cited by 40
Fiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39
“Furthermore, a study that explored 74 mesothelioma tumors using a genomic analysis identified TGF-β1 mRNA expression as being correlated with the worst patient prognoses [40].”
BackgroundFu, Y., Guo, X., Sun, L., Cui, T., Wu, C., Wang, J., Liu, Y., & Liu, L. (2024) · eLife · doi:10.7554/elife.95009 · Cited by 39
Self-citationPass, H. I., Alimi, M., Carbone, M., Yang, H., & Goparaju, C. M. V. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0083 · Cited by 39
Self-citationFast Cross-validation for Multi-penalty High-dimensional Ridge Regression
van de Wiel, M. A., van Nee, M. M., & Rauschenberger, A. (2021) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.2021.1904962 · Cited by 39
Gu, Y., Wang, Y., Sha, Z., He, C., Zhu, Y., Li, J., Yu, A., Zhong, Z., Wang, X., Sun, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111296 · Cited by 39
Recent progress and perspectives on the mechanisms underlying Asbestos toxicity
Kuroda, A. (2021) · Genes and Environment · doi:10.1186/s41021-021-00215-0 · Cited by 38
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma
Zhang, M., Bzura, A., Baitei, E. Y., Zhou, Z., Spicer, J., Poile, C., Rogel, J., Branson, A., King, A., Barber, S. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49842-5 · Cited by 38
Self-citationEmerging avenues in immunotherapy for the management of malignant pleural mesothelioma
Gray, S. G. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01513-7 · Cited by 38
A critical review of the 2020 EPA risk assessment for chrysotile and its many shortcomings
Paustenbach, D. J., Brew, D., Ligas, S., & Heywood, J. (2021) · Critical Reviews in Toxicology · doi:10.1080/10408444.2021.1968337 · Cited by 38
Karpes, J. B., Shamavonian, R., Dewhurst, S., Cheng, E. M., Wijayawardana, R., Ahmadi, N., & Morris, D. L. (2023) · Cancers · doi:10.3390/cancers15194704 · Cited by 36
Chromosomal rearrangements and their neoantigenic potential in mesothelioma
Mansfield, A. S., Peikert, T., & Vasmatzis, G. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.12 · Cited by 35
Febres‐Aldana, C. A., Chang, J. C., Jungbluth, A. A., Adusumilli, P. S., Bodd, F. M., Frosina, D., Geronimo, J. A., Hernandez, E., Irawan, H., Offin, M. D., et al. (2024) · Modern Pathology · doi:10.1016/j.modpat.2023.100420 · Cited by 35
Self-citationTagliamento, M., Morfouace, M., Loizides, C., Oliveira, J., Greillier, L., Raimbourg, J., Toffart, A., Chatellier, T., Cloarec, N., Sullivan, I., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00518-9 · Cited by 35
Hotta, K., & Fujimoto, N. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000461 · Cited by 35
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells
Bonelli, M. A., Terenziani, R., Zoppi, S., Fumarola, C., Monica, S. L., Cretella, D., Alfieri, R. R., Cavazzoni, A., Digiacomo, G., Galetti, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145165 · Cited by 35
Hand2 delineates mesothelium progenitors and is reactivated in mesothelioma
Prummel, K. D., Crowell, H. L., Nieuwenhuize, S., Brombacher, E. C., Daetwyler, S., Soneson, C., Kresoja‐Rakic, J., Kocere, A., Ronner, M., Ernst, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29311-7 · Cited by 35
Đačić, S., Stang, N. L., Husain, A. N., Weynand, B., Beasley, M. B., Butnor, K. J., Chapel, D. B., Gibbs, A. R., Klebe, S., Lantuéjoul, S., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0320-y · Cited by 35
Self-citationThe Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
Désage, A.-L., Karpathiou, G., Peoc’h, M., & Froudarakis, M. E. (2021) · Cancers · doi:10.3390/cancers13133205 · Cited by 34
Nguyen, T. N. A., Lai, H.-T., Fernandes, R., Dall’Olio, F. G., Blériot, C., Ha‐Duong, T., & Brenner, C. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02272-2 · Cited by 34
Wang, Y., Zhu, Y., Gu, Y., Ma, M., Wang, Y., Qi, S., Zeng, Y. J., Zhu, R., Wang, X., Yu, P., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109596 · Cited by 34
Perrino, M., Vincenzo, F. D., Cordua, N., Borea, F., Aliprandi, M., Santoro, A., & Zucali, P. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121557 · Cited by 34
Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma
Xu, D., Yang, H., Zhang, Y., Berezowska, S., Gao, Y., Liang, S., Marti, T. M., Hall, S. R. R., Dorn, P., Kocher, G. J., et al. (2019) · Cancers · doi:10.3390/cancers11101502 · Cited by 33
Jang, H.-J., Truong, C., Lo, E. M., Holmes, H. M., Ramos, D., Ramineni, M., Lee, J., Wang, D. Y., Pietropaolo, M., Ripley, R. T., et al. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.08.054 · Cited by 33
CpG Island Methylator Phenotype—A Hope for the Future or a Road to Nowhere?
Karpiński, P., & Sasiadek, M. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020830 · Cited by 33
Meng, X., Xiong, Z., Xiao, W., Yuan, C., Wang, C., Huang, Y., Tong, J., Shi, J., Chen, Z., Liu, C., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.141 · Cited by 32
Chen, R., Lee, W., Fujimoto, J., Li, J., Hu, X., Mehran, R. J., Rice, D. C., Swisher, S. G., Sepesi, B., Tran, H. T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1767 · Cited by 32
Self-citationNair, N. U., Jiang, Q., Wei, J. S., Misra, V. A., Morrow, B., Kesserwan, C. A., Hermida, L. C., Lee, J. S., Mian, I., Zhang, J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100938 · Cited by 33
Self-citationBiological Basis for Novel Mesothelioma Therapies
Obacz, J., Yung, H., Shamseddin, M., Linnane, E., Liu, X., Azad, A. A., Rassl, D. M., Fairen-Jimenez, D., Rintoul, R. C., Nikolić, M. Z., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01462-2 · Cited by 31
Self-citationde Perrot, M. E., Wu, L., Cabanero, M., Perentes, J. Y., McKee, T. D., Donahoe, L. L., Bradbury, P. A., Kohno, M., Chan, M.-L., Murakami, J., et al. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.10.122 · Cited by 31
Genomics and Functional Genomics of Malignant Pleural Mesothelioma
Çakıroğlu, E., & Şentürk, Ş. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176342 · Cited by 31
Use of preclinical models for malignant pleural mesothelioma
Shamseddin, M., Obacz, J., Garnett, M. J., Rintoul, R. C., Francies, H. E., & Marciniak, S. J. (2021) · Thorax · doi:10.1136/thoraxjnl-2020-216602 · Cited by 32
Self-citationSun, S., Frontini, F., Qi, W., Hariharan, A., Ronner, M., Wipplinger, M., Blanquart, C., Rehrauer, H., Fonteneau, J., & Felley‐Bosco, E. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.004 · Cited by 31
Ramarao-Milne, P., Kondrashova, O., Patch, A., Nones, K., Koufariotis, L. T., Newell, F., Addala, V., Lakis, V., Holmes, O., Leonard, C., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100540 · Cited by 31
Self-citationGridnev, A., Maity, S., & Misra, J. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1021823 · Cited by 31
Xu, D., Gao, Y., Yang, H., Spils, M., Marti, T. M., Losmanová, T., Su, M., Wang, W., Zhou, Q., Dorn, P., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100672 · Cited by 30
Chevrier, M., Monaco, S. E., Jerome, J. A., Galateau-Sallé, F., Churg, A., & Đačić, S. (2020) · Cancer Cytopathology · doi:10.1002/cncy.22326 · Cited by 30
Self-citationAn Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma
Davis, A. P., Ke, H., Kao, S., & Pavlakis, N. (2022) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s288535 · Cited by 30
Mannarino, L., Paracchini, L., Pezzuto, F., Olteanu, G., Moracci, L., Vedovelli, L., Simone, I. D., Bosetti, C., Lupi, M., Amodeo, R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105786 · Cited by 30
Pan-cancer atlas of somatic core and linker histone mutations
Bonner, E. R., Dawood, A., Gordish‐Dressman, H., Eze, A., Bhattacharya, S., Yadavilli, S., Mueller, S. C., Waszak, S. M., & Nazarian, J. (2023) · npj Genomic Medicine · doi:10.1038/s41525-023-00367-8 · Cited by 30
Asbestos and ovarian cancer: examining the historical evidence
Slomovitz, B. M., de Haydu, C., Taub, M., Coleman, R. L., & Monk, B. J. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001672 · Cited by 30
Statistical genomics in rare cancer
Abbas-Aghababazadeh, F., Mo, Q., & Fridley, B. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.021 · Cited by 26
Marqués, M., Tranchant, R., Risa-Ebrí, B., Suárez-Solís, M. L., Fernández, L. C., Pau, E. C. D. S., del Pozo, N., de Villarreal, J. M., Meiller, C., Allory, Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1633 · Cited by 29
KRAS signaling in malignant pleural mesothelioma
Marazioti, A., Krontira, A. C., Behrend, S. J., Giotopoulou, G. A., Ntaliarda, G., Blanquart, C., Bayram, H., Iliopoulou, M. P., Vreka, M., Trassl, L., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013631 · Cited by 29
Molecular and immunohistochemical characterisation of mesothelioma of the tunica vaginalis*
Anderson, W. J., Sholl, L. M., Fletcher, C. D. �., Schulte, S., Wang, L., Maclean, F. M., & Hirsch, M. S. (2022) · Histopathology · doi:10.1111/his.14669 · Cited by 29
Okonska, A., Bühler, S., Rao, V., Ronner, M., Blijlevens, M., van der Meulen‐Muileman, I. H., de Menezes, R. X., Wipplinger, M., Oehl, K., Smit, E. F., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0356 · Cited by 29
Orbach, D. H., André, N., Brecht, I. B., Almaraz, R. L., Ben‐Ami, T., Vermersch, S., Carton, M., Virgone, C., Bisogno, G., Schneider, D. T., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.011 · Cited by 28
Self-citationIntegrated genomics point to immune vulnerabilities in pleural mesothelioma
Năstase, A., Mandal, A., Lu, S. K., Anbunathan, H., Morris-Rosendahl, D. J., Zhang, Y. Z., Sun, X. M., Gennatas, S., Rintoul, R. C., Edwards, M. M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98414-w · Cited by 28
Self-citationFennell, D. A., Porter, C., Lester, J. F., Danson, S. J., Taylor, P., Sheaff, M. T., Rudd, R., Gaba, A., Busacca, S., Nixon, L. S., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101432 · Cited by 28
Abba, M. C., Canzoneri, R., Gurruchaga, A., Lee, J., Tatineni, P., Kil, H., Lacunza, E., & Aldaz, C. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197407 · Cited by 28
Alay, A., Cordero, D., Hijazo‐Pechero, S., Aliagas, E., López‐Doriga, A., Marín, R., Palmero, R., Llatjós, R., Escobar, I., Ramos, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001601 · Cited by 28
Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study
Pagano, M., Ceresoli, L. G., Zucali, P. A., Pasello, G., Garassino, M. C., Grosso, F., Tiseo, M., Parra, H. J. S., Zanelli, F., Cappuzzo, F., et al. (2020) · Cancers · doi:10.3390/cancers12102948 · Cited by 26
Brich, S., Bozzi, F., Perrone, F., Tamborini, E., Cabras, A. D., Deraco, M., Stacchiotti, S., Dagrada, G. P., & Pilotti, S. (2019) · Modern Pathology · doi:10.1038/s41379-019-0371-0 · Cited by 26
Stockhammer, P., Plönes, T., Theegarten, D., Schüler, M., Maier, S. M., Aigner, C., & Hegedűs, B. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.11.013 · Cited by 27
Pezzuto, F., Serio, G., Fortarezza, F., Scattone, A., Caporusso, C., Punzi, A., Cavone, D., Pennella, A., Marzullo, A., & Vimercati, L. (2020) · Diagnostics · doi:10.3390/diagnostics10060386 · Cited by 26
An overview of BAP1 biological functions and current therapeutics
Elsayed, A. M., Kittaneh, M., Cebulla, C. M., & Abdel‐Rahman, M. H. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189267 · Cited by 25
MicroRNA-206 suppresses mesothelioma progression via the Ras signaling axis
Singh, A. N., Pruett, N. D., Pahwa, R., Mahajan, A., Schrump, D. S., & Hoang, C. D. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.04.001 · Cited by 25
Bertero, L., Righi, L., Collemi, G., Koelsche, C., Hou, Y., Stichel, D., Schrimpf, D., Flucke, U. E., Petersen, I., Vokuhl, C., et al. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.04.002 · Cited by 25
Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ
Đačić, S., Roy, S., Lyons, M. A., von der Thüsen, J. H., Galateau-Sallé, F., & Churg, A. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.09.002 · Cited by 25
Self-citationYoshikawa, Y., Kuribayashi, K., Minami, T., Ohmuraya, M., & Kijima, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554570 · Cited by 25
Self-citationMalignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis
Xu, D., Liang, S., Zhang, Y., Yang, H., Bruggmann, R., Oberhaensli, S., Berezowska, S., Marti, T. M., Hall, S. R. R., Dorn, P., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03668-x · Cited by 25
G�rard, M., Chatelain, C., Delaunay, T., Tostivint, E. P., Bennouna, J., & Fonteneau, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.695770 · Cited by 25
Kosari, F., Disselhorst, M., Yin, J., Peikert, T., Udell, J. B. M., Johnson, S. H., Smadbeck, J. B., Murphy, S. J., McCune, A., Karagouga, G., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.022 · Cited by 25
Expression of V-set immunoregulatory receptor in malignant mesothelioma
Chung, Y. S., Kim, M., Cha, Y. J., Kim, K., & Shim, H. S. (2019) · Modern Pathology · doi:10.1038/s41379-019-0328-3 · Cited by 25
Dermawan, J. K. T. K., Torrence, D. E., Lee, C., Villafania, L. B., Mullaney, K. A., DiNapoli, S. E., Sukhadia, P., Benayed, R., Borsu, L. A., Agaram, N. P., et al. (2022) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23074 · Cited by 24
Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment
Febres‐Aldana, C. A., Fanaroff, R. E., Offin, M. D., Zauderer, M. G., Sauter, J. L., Yang, S., & Ladanyi, M. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042420-092719 · Cited by 25
Self-citationDudnik, E., Bar, J., Moore, A., Gottfried, T., Moskovitz, M. T., Dudnik, J., Shochat, T., Allen, A. M., Zer, A., Rotem, O., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.603223 · Cited by 24
Identification of Overexpressed Genes in Malignant Pleural Mesothelioma
Morani, F., Bisceglia, L., Rosini, G., Mutti, L., Melaiu, O., Landi, S., & Gemignani, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052738 · Cited by 24
Molecular Fingerprints of Malignant Pleural Mesothelioma: Not Just a Matter of Genetic Alterations
Lorenzini, E., Ciarrocchi, A., & Torricelli, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112470 · Cited by 24
Repurposing RNA sequencing for discovery of RNA modifications in clinical cohorts
Tan, K., Ding, L., Wu, C.-S., Tenen, D. G., & Yang, H. H. (2021) · Science Advances · doi:10.1126/sciadv.abd2605 · Cited by 24
Liu, X., Fu, Q., Bian, X., Fu, Y., Xin, J., Liang, N., Li, S., Zhao, Y., Li, F., Li, C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.600927 · Cited by 23
Self-citationGenetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma
Pandey, G. K., Landman, N., Neikes, H. K., Hulsman, D., Lieftink, C., Beijersbergen, R. L., Kolluri, K. K., Janes, S. M., Vermeulen, M., Badhai, J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100915 · Cited by 23
Mesotheliomas and Benign Mesothelial Tumors: Update on Pathologic and Imaging Findings
Bonde, A. A., Singh, R., Prasad, S. R., Kamireddy, D., Aggarwal, A., Ramani, N. S., Saboo, S. S., Shanbhogue, K., Dasyam, A. K., & Katabathina, V. S. (2023) · Radiographics · doi:10.1148/rg.220128 · Cited by 23
Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions
Hung, Y. P., & Chirieac, L. R. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0213-ra · Cited by 24
Self-citationImmunotherapy in malignant pleural mesothelioma: a review of literature data
Menis, J., Pasello, G., & Remón, J. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-673 · Cited by 23
Napoli, F., Listì, A., Zambelli, V., Witel, G., Bironzo, P., Papotti, M., Volante, M., Scagliotti, G., & Righi, L. (2021) · Cancers · doi:10.3390/cancers13112564 · Cited by 22
“This was particularly observed in the epithelioid subtype and strongly correlated with mesothelin expression [11].”
BackgroundStatistical Methods for Integrative Clustering of Multi-omics Data
Chalise, P., Kwon, D., Fridley, B. L., & Mo, Q. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-2986-4_5 · Cited by 22
New developments in mesothelial pathology
Churg, A. (2023) · Histopathology · doi:10.1111/his.15007 · Cited by 22
Cheung, M., Kadariya, Y., Sementino, E., Hall, M. J., Cozzi, I., Ascoli, V., Ohar, J. A., & Testa, J. R. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab138 · Cited by 22
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma
Aliagas, E., Alay, A., Martínez‐Iniesta, M., Hernández-Madrigal, M., Cordero, D., Gausachs, M., Pros, E., Saigí, M., Busacca, S., Sharkley, A. J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01547-y · Cited by 22
Immune checkpoint inhibition for the treatment of mesothelioma
Nowak, A. K., McDonnell, A. M., & Cook, A. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1606209 · Cited by 21
Mesothelioma in the age of “Omics”: Before and after The Cancer Genome Atlas
Severson, D. T., Rienzo, A. D., & Bueno, R. (2020) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2020.02.141 · Cited by 21
Self-citationLapidot, M., Case, A. E., Larios, D., Gandler, H. I., Meng, C., Tošić, I., Weisberg, E., Poitras, M. J., Gokhale, P. C., Paweletz, C. P., et al. (2020) · Cancers · doi:10.3390/cancers13010007 · Cited by 21
Self-citationVecchio, E., Gallo, R., Mimmi, S., Gentile, D., Giordano, C., Straface, E., Marino, R., Caiazza, C., Pastore, A., Ruocco, M. R., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-07754-0 · Cited by 20
Dagogo‐Jack, I., Mitchell, O. D., Codd, E. M., Li, A., Mitchell, D. R., Flynn, S. E., Sivamanoharan, N., Reeves, P. M., Poznansky, M. C., Valiev, I., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.06.018 · Cited by 20
Self-citationTranslating mesothelioma molecular genomics and dependencies into precision oncology-based therapies
Hinz, T. K., & Heasley, L. E. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.014 · Cited by 20
Hu, J., Zhang, B., Yao, F., Fu, Y., Chen, D., Li, D., Du, N., Lizaso, A., Song, J., Zhang, L., et al. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620935770 · Cited by 20
AXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 Expression
Song, W., Wang, H., Lu, M., Ni, X., Bahri, N., Zhu, S., Chen, L., Wu, Y., Qiu, J., Fletcher, J. A., et al. (2020) · Cancers · doi:10.3390/cancers12102757 · Cited by 20
Self-citationDehner, C. A., Geiersbach, K. B., Rowsey, R. A., Murugan, P., Broski, S. M., Meis, J. M., Rosenberg, A. E., & Folpe, A. L. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100131 · Cited by 20
Homicskó, K., Zygoura, P., Norkin, M., Tissot, S., Shakarishvili, N., Popat, S., Fontecedro, A. C., O'Brien, M. E. R., Pope, A., Shah, R. N. H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007585 · Cited by 20
Ayton, S. G., Pavlicová, M., Robles‐Espinoza, C. D., Tamez‐Peña, J. G., & Treviño, V. (2021) · Genetics in Medicine · doi:10.1016/j.gim.2021.09.006 · Cited by 20
Metadata
- Authors
- Hmeljak, J., Sanchez-Vega, F., Hoadley, K. A., Shih, J., Stewart, C., Heiman, D., Tarpey, P., Danilova, L., Drill, E., Gibb, E. A., Bowlby, R., Kanchi, R., Osmanbeyoglu, H. U., Sekido, Y., Takeshita, J., Newton, Y., Graim, K., Gupta, M., Gay, C. M., Diao, L., Gibbs, D. L., Thorsson, V., Iype, L., Kantheti, H., Severson, D. T., Ravegnini, G., Desmeules, P., Jungbluth, A. A., Travis, W. D., Dacic, S., Chirieac, L. R., Galateau-Sallé, F., Fujimoto, J., Husain, A. N., Silveira, H. C., Rusch, V. W., Rintoul, R. C., Pass, H., Kindler, H., Zauderer, M. G., Kwiatkowski, D. J., Bueno, R., Tsao, A. S., Creaney, J., Lichtenberg, T., Leraas, K., Bowen, J., TCGA Research Network, Felau, I., Zenklusen, J. C., Akbani, R., Cherniack, A. D., Byers, L. A., Noble, M. S., Fletcher, J. A., Robertson, A. G., Shen, R., Aburatani, H., Robinson, B. W., Campbell, P., Ladanyi, M., Aburatani, H., Akbani, R., Ally, A., Anur, P., Armenia, J., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., Becich, M., Behrens, C., Beroukhim, R., Bielski, C., Bodenheimer, T., Bootwalla, M. S., Bowen, J., Bowlby, R., Brooks, D., Bueno, R., Byers, L. A., Cárcano, F. M., Carlsen, R., Carvalho, A. L., Cherniack, A. D., Cheung, D., Chirieac, L., Cho, J., Chuah, E., Chudamani, S., Cibulskis, C., Cope, L., Crain, D., Creaney, J., Curley, E., Dacic, S., Danilova, L., Rienzo, A. D., DeFreitas, T., Demchok, J. A., Dhalla, N., Dhir, R., Diao, L., Drill, E., Felau, I., Feldman, M., Ferguson, M. L., Fletcher, J. A., Fujimoto, J., Fujimoto, J., Fukuda, S., Gabriel, S. B., Sallé, F. G., Gao, J., Gardner, J., Gastier-Foster, J. M., Gay, C. M., Gehlenborg, N., Gerken, M., Getz, G., Gibb, E. A., Gibbs, D. L., Goparaju, C., Graim, K., Gross, B., Guo, G., Gupta, M., Hasegawa, S., Haussler, D., Hayes, D. N., Heiman, D. I., Heins, Z., Hmeljak, J., Hoadley, K. A., Holt, R. A., Hoyle, A. P., Husain, A., Hutter, C. M., Iype, L., Jefferys, S. R., Jones, S. J. M., Jones, C. D., Kanchi, R. S., Kasaian, K., Kim, J., Kindler, H., Kondo, N., Krausz, T., Kundra, R., Kuribayashi, K., Kwiatkowski, D. J., Ladanyi, M., Lai, P. H., Laird, P. W., Lawrence, M. S., Lee, D., Leraas, K. M., Lichtenberg, T. M., Lin, P., Liu, J., Liu, W., Liu, E. M., Lolla, L., Longatto-Filho, A., Lu, Y., Luketich, J., Ma, Y., Maglinte, D. T., Mallory, D., Marra, M. A., Mayo, M., Meier, S., Melamed, J., Meng, S., Meyerson, M., Mieczkowski, P. A., Mills, G. B., Moore, R. A., Moran, C., Morris, S., Mose, L. E., Mungall, A. J., Mungall, K., Nakano, T., Naresh, R., Newton, Y., Noble, M. S., Ochoa, A., Osmanbeyoglu, H., Parker, J. S., Pass, H. I., Paulauskis, J., Pennathur, A., Pennell, N. A., Penny, R., Perou, C. M., Pihl, T., Ramirez, N. C., Rassl, D. M., Ravegnini, G., Reid, G., Reis, R. M., Reynolds, S. M., Rice, D., Richards, W. G., Rintoul, R. C., Roach, J., Robertson, A. G., Rusch, V., Sadeghi, S., Saksena, G., Sanchez-Vega, F., Sander, C., Sato, A., Scapulatempo-Neto, C., Schein, J. E., Schultz, N., Schumacher, S. E., Seiwert, T., Sekido, Y., Severson, D. T., Shelton, C., Shelton, T., Shen, R., Sheridan, R., Shi, Y., Shih, J., Shiraishi, Y., Shmulevich, I., Silveira, H. C. S., Simons, J. V., Sipahimalani, P., Skelly, T., Sofia, H. J., Soloway, M. G., Spellman, P., Stewart, C., Stuart, J., Sun, Q., Takeshita, J., Tam, A., Tan, D., Tarnuzzer, R., Tatsuno, K., Taylor, B. S., Thiessen, N., Thompson, E., Thorsson, V., Travis, W. D., Tsao, A., Tse, K., Tsujimura, T., Valdivieso, F., Van Den Berg, D. J., van Zandwijk, N., Veluvolu, U., Viana, L. S., Voet, D., Wan, Y., Wang, Z., Wang, J., Weaver, J., Weinstein, J. N., Weisenberger, D. J., Wilkerson, M. D., Wise, L., Wistuba, I., Wong, T., Wu, Y., Yamamoto, S., Yang, L., Zauderer, M. G., Zenklusen, J. C., Zhang, J., Zhang, H., Zhang, H., & Zmuda, E.
- Affiliations
- 3Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
- Wellcome Sanger Institute (GB)
- 10Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 11Computational Systems Biology, Memorial Sloan Kettering Cancer Center, New York, New York.
- The University of Texas at Dallas (US)
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Memorial Sloan Kettering Cancer Center (US)
- 23Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
- 24MESOPATH. Cancer Center Leon Berard, Lyon, France.
- 26Department of Pathology, University of Chicago, Chicago, Illinois.
- 27Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil.
- 28Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
- 30Department of Cardiothoracic Surgery, NYU Langone Medical Center, New York, New York.
- 15Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 35The Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
- 36National Cancer Institute, Bethesda, Maryland.
- 18Division of Thoracic Surgery, The Lung Center and International Mesothelioma Program, Brigham and Women's Hospital, Boston, Massachusetts.
- The University of Western Australia (AU)
- ORCID
- Tarpey, Patrick
- Kantheti, Havish
- Desmeules, Patrice
- Jungbluth, Achim A.
- Silveira, Henrique C.
- Tsao, Anne S.
- Robinson, Bruce W.
- Campbell, Peter
- Armenia, Joshua
- Auman, J. Todd
- Baylin, Stephen B.
- Becich, Michael
- Behrens, Carmen
- Beroukhim, Rameen
- Bootwalla, Moiz S.
- Cibulskis, Carrie
- Cope, Leslie
- Rienzo, Assunta De
- Dhir, Rajiv
- Ferguson, Martin L.
- Fukuda, Shiro
- Gabriel, Stacey B.
- Gao, Jianjiong
- Gehlenborg, Nils
- Getz, Gad
- Goparaju, Chandra
- Gross, Benjamin
- Guo, Guangwu
- Hasegawa, Seiki
- Haussler, David
- Hayes, D. Neil
- Heins, Zachary
- Holt, Robert A.
- Hoyle, Alan P.
- Jefferys, Stuart R.
- Jones, Steven J.M.
- Jones, Corbin D.
- Kasaian, Katayoon
- Kim, Jaegil
- Kondo, Nobuyuki
- Kundra, Ritika
- Kuribayashi, Kozo
- Laird, Peter W.
- Lawrence, Michael S.
- Lee, Darlene
- Lin, Pei
- Liu, Jia
- Liu, Wenbin
- Liu, Eric Minwei
- Lu, Yiling
- Luketich, James
- Maglinte, Dennis T.
- Marra, Marco A.
- Mayo, Michael
- Melamed, Jonathan
- Meyerson, Matthew
- Mieczkowski, Piotr A.
- Mills, Gordon B.
- Mungall, Andrew J.
- Nakano, Takashi
- Ochoa, Angelica
- Parker, Joel S.
- Pennathur, Arjun
- Pennell, Nathan A.
- Perou, Charles M.
- Pihl, Todd
- Ramirez, Nilsa C.
- Rassl, Doris M.
- Reid, Glen
- Reis, Rui M.
- Rice, David
- Richards, William G
- Roach, Jeffrey
- Sadeghi, Sara
- Saksena, Gordon
- Sander, Chris
- Sato, Ayuko
- Schultz, Nikolaus
- Schumacher, Steven E.
- Seiwert, Tanguy
- Shi, Yan
- Shiraishi, Yuichi
- Sofia, Heidi J.
- Spellman, Paul
- Sun, Qiang
- Tam, Angela
- Tarnuzzer, Roy
- Tatsuno, Kenji
- Taylor, Barry S
- Tsujimura, Tohru
- Wang, Jing
- Weaver, Joellen
- Weinstein, John N.
- Weisenberger, Daniel J.
- Wilkerson, Matthew D.
- Wistuba, Ignacio
- Wong, Tina
- Wu, Ye
- Yamamoto, Shogo
- Yang, Liming
- Zhang, Jiashan
- Zhang, Hailei
- Zhang, Hongxin
- Zmuda, Erik
- Venue
- Cancer Discovery
- Published
- 2018-12-01
- Volume
- 8
- Issue
- 12
- Pages
- 1548-1565
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6310008
- OpenAlex
- W2897299514
- Cited by
- 618
- References
- 62
- Citations by year
- 2026: 53 · 2025: 62 · 2024: 61 · 2023: 78 · 2022: 96 · 2021: 117 · 2020: 100 · 2019: 45 · 2018: 4
- FWCI
- 50.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Funders
- HHS | National Institutes of Health (NIH) (U54 HG003273, U24 CA143858, U24 CA143866, U24 CA143867, U24 CA143882, U24 CA143883, U24 CA144025, P30 CA016672, P30 CA008748, U54 HG003067, U54 HG003079, U24 CA143799, U24 CA143835, U24 CA143840, U24 CA143843, U24 CA143845, U24 CA143848)
- British Lung Foundation (BLF) (APG11-7)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- malignant pleural mesothelioma, TP53 mutation, loss of heterozygosity, genomic subtypes, VISTA, immune checkpoint, epithelioid mesothelioma, immunotherapy, antitumor immunity
- MeSH terms
- Aged, Female, Humans, Lung Neoplasms, Male, Mesothelioma, Middle Aged, Mutation, Pleural Neoplasms, Prognosis, Histone-Lysine N-Methyltransferase, Protein Methyltransferases, Biomarkers, Tumor, Tumor Suppressor Proteins, Ubiquitin Thiolesterase, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.